---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-041223"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T04:02:44.645220+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics reports Q3 net loss of $2.0M; cash increases to $10.1M after business combination

## Summary
- Net loss of $2.0M ($0.14 per share) for Q3 2023 versus $5.4M loss ($0.63 per share) for Q3 2022.
- R&D expenses rose to $3.3M from $1.9M; G&A decreased to $4.0M from $5.0M.
- Cash and restricted cash of $10.3M as of Sept 30, 2023, versus $0.6M at Dec 31, 2022, reflecting business combination.
- First patient dosed by City of Hope in Phase 1 trial of CLD-101 for recurrent high-grade glioma; interim data expected 1H2024.
- Appointed Andrew Jackson as CFO and Alan Stewart to Board of Directors.

## SEC filing metadata
- accession: 0001493152-23-041223
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315223041223/0001493152-23-041223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315223041223/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-041223
- JSON: https://secwatch.observer/filing/0001493152-23-041223.json
- Plain text: https://secwatch.observer/filing/0001493152-23-041223.txt

## Key facts
- Earnings Releases
  Calidi Biotherapeutics, Inc. reported third quarter 2023 results: net income $2.0 million, or $0.14 per share, EPS $0.14 per share.
  - Period: third quarter 2023
  - Net income: $2.0 million, or $0.14 per share
  - EPS: $0.14 per share
  - Result: reported results
  source text: The company reported a net loss of $2.0 million, or $0.14 per share, for the three months ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315223041223/0001493152-23-041223-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.